Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry.
Michael GugerChristian EnzingerFritz LeutmezerFranziska Di PauliJörg KrausStefan KalcherErich KvasThomas Bergernull nullPublished in: Journal of neurology (2021)
These real-life data show a stable disease course regarding relapse activity and disease progression under NTZ treatment for more than 7 years. The main predictors for disease activity were higher relapse rate before treatment initiation, higher disability, shorter disease duration and absence of Gadolinium-enhancing MRI lesions at baseline. Older age at NTZ start was the only significant risk factor for disease progression over long-term.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- multiple sclerosis
- rheumatoid arthritis patients
- ankylosing spondylitis
- magnetic resonance imaging
- juvenile idiopathic arthritis
- electronic health record
- big data
- computed tomography
- combination therapy
- contrast enhanced
- replacement therapy
- community dwelling